| 2023/12/01 16:30:07 | |
|---|---|
| Price | |
| 131.50 EUR | |
| Difference | 1.39% (1.80) |
General attributes
| ISIN | US00287Y1091 |
| Symbol | ABBV |
| Exchange | Duesseldorf |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 230,818 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 131.60 EUR (230) |
| Ask (Ask size) | 132.00 EUR (230) |
| Open | 129.90 EUR |
| High | 131.50 EUR |
| Low | 129.90 EUR |
| Close (prev. day) | 129.70 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 4 |
| Last size | 0 |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: ABBVIE INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/11/24 |
|
Global Equity Ratings |
|
| 2023/10/27 |
|
Global Equity Ratings |
|
| 2023/09/29 |
|
Global Equity Ratings |
|
| 2023/09/08 |
|
Global Equity Ratings |
|
| 2023/08/22 |
|
Global Equity Ratings |
|
| 2023/12/01 16:30:07 | |
|---|---|
| Price | |
| 131.50 EUR | |
| Difference | 1.39% (1.80) |
General attributes
| ISIN | US00287Y1091 |
| Symbol | ABBV |
| Exchange | Duesseldorf |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 230,818 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 131.60 EUR (230) |
| Ask (Ask size) | 132.00 EUR (230) |
| Open | 129.90 EUR |
| High | 131.50 EUR |
| Low | 129.90 EUR |
| Close (prev. day) | 129.70 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 4 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +2.45% | -15.60% | +48.14% |
| Perf (abs.) | +3.10 | -23.98 | +42.15 |
| Beta | 0.24 | 0.19 | 0.36 |
| Volatility | 23.65 | 22.07 | 24.02 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 127.02 EUR (5) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 130.73 EUR (2) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 135.04 EUR (2) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 137.23 EUR (4) |
| YTD High | date | 158.06 EUR (2023/01/06) |
| YTD Low | date | 118.90 EUR (2023/07/13) |
| 52 Weeks High | date | 158.06 EUR (2023/01/06) |
| 52 Weeks Low | date | 118.90 EUR (2023/07/13) |
All listings for ABBVIE INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| BX Swiss | 2023/11/21 | 18:00 | 122.909 CHF | 0.01 | 2 |
| Berlin | 2023/12/01 | 17:40 | 131.40 EUR | 0.00 | 12 |
| Duesseldorf | 2023/12/01 | 16:30 | 131.50 EUR | 0.00 | 4 |
| Frankfurt | 2023/12/01 | 11:31 | 131.10 EUR | 0.02 | 6 |
| London Stock Exchange European Trade Reporting | 2023/12/01 | 17:30 | 142.75 USD | 0.00 | 5 |
| Munich | 2023/12/01 | 08:04 | 130.10 EUR | 0.00 | 1 |
| NYSE | 2023/12/01 | 18:12 | 143.37 USD | 242.29 | 34,223 |
| Stuttgart | 2023/12/01 | 18:11 | 131.90 EUR | 0.01 | 5 |
| Tradegate | 2023/12/01 | 18:10 | 131.90 EUR | 0.91 | 113 |
| Vienna Stock Exchange | 2023/12/01 | 17:32 | 131.60 EUR | 0.00 | 2 |
| Xetra | 2023/12/01 | 17:35 | 131.40 EUR | 0.19 | 34 |
Company Logo
Contact Details
| ABBVIE INC. |
| - - |
| 1 North Waukegan Road - 60064-6400 North Chicago |
| Telefon: +1-847-932-7900 |
| Fax: + |
| E-mail: - |
PDF Downloads
| Company report: ABBVIE INC. | |
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |
Members of Management Board
| Robert Alpern | Member of Board of Directors |
| Susan Quaggin | Member of Board of Directors |
| Brett Hart | Member of Board of Directors |
| Edward Rapp | Member of Board of Directors |
| Frederick Waddell | Member of Board of Directors |
| Glenn Tilton | Member of Board of Directors |
| Jennifer Davis | Member of Board of Directors |
| Melody Meyer | Member of Board of Directors |
| Rebecca Roberts | Member of Board of Directors |
| Robert Michael | Member of Board of Directors |
| Roxanne Austin | Member of Board of Directors |
| Thomas Freyman | Member of Board of Directors |
| William Burnside | Member of Board of Directors |
| Richard A. Gonzalez | Chairman of Managing Board |
| Azita Saleki-Gerhardt | Member of Executive Committee |
| Carrie Strom | Member of Executive Committee |
| Henry O. Gosebruch | Member of Executive Committee |
| Jeffrey R. Stewart | Member of Executive Committee |
| Laura J. Schumacher | Member of Executive Committee |
| Perry C. Siatis | Member of Executive Committee |
| Rae L. Livingston | Member of Executive Committee |
| Robert A. Michael | Member of Executive Committee |
| Scott T. Reents | Member of Executive Committee |
| Timothy J. Richmond | Member of Executive Committee |